Wavelength-Pharmaceuticals-Insert
X

Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ibutilide

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Premier Intermediates Pvt.Ltd.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 19, 2020

            Details:

            Premier’s ProvideGx program identifies safe, high-quality supply sources for drugs that are or may be at risk of being added to the national drug shortage list.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mexiletine

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 23, 2020

            Details:

            Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a percentage of net profits. Other financial terms were not disclosed.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dapagliflozin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Farxiga

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 16, 2020

            Details:

            The designation is based on the Phase III DAPA-MI trial that will explore the efficacy and safety of Farxiga in this patient population. Acute MI is a serious condition and a known cause of heart failure (HF). Approximately seven million heart attacks occur globally each year.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Landiolol Hydrochloride

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Onoact

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            Details:

            This approval is based on the result of a multi-center, randomized, open-label, parallel-group, late Phase Ⅱ / Ⅲ study (J-Land 3S study: ONO-1101-32) conducted in Japan, in patients with tachyarrhythmia associated with sepsis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SOTALOL HCI

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $69.3 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 26, 2020

            Details:

            This significant raise will support Hyloris’ strategy and will be used for the development of existing portfolio of product candidates, establishment of a commercial team in the United States, to fund the expansion of the pipeline, as well as for general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dapagliflozin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Farxiga

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2020

            Details:

            The SGLT2 inhibitor dapagliflozin, when used in patients with heart failure, provided a benefit in preventing type 2 diabetes (T2D).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dapagliflozin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Farxiga

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 11, 2020

            Details:

            An oral presentation of data from the DAPA-HF trial showing the effect of Farxiga (dapagliflozin) on the incidence of new onset of type-2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ticagrelor,Aspirin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 01, 2020

            Details:

            The approval was based on positive results from the Phase III THEMIS trial. The trial showed a statistically significant reduction in the primary composite endpoint of MACE at 36 months with aspirin + Brilinta 60mg versus aspirin alone in patients with CAD and type-2 diabetes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bone marrow-derived allogeneic mesenchymal stromal cells

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Novumcella

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 28, 2020

            Details:

            As per the agreement, Novumcella will initially provide regulatory support services to Stempeutics for getting approval from PMDA, Japan for conduct of bridge study in Japan for commercializing Stempeucel® product for Buerger’s Disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Enoxaparin Sodium

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 28, 2020

            Details:

            Meitheal Pharmaceuticals has launched Enoxaparin Sodium Injection, generic equivalent of Lovenox®, in the United States market. Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.

            PharmaCompass